AASLD 2025

InSphero is attending AASLD 2025!

Don't miss the chance to connect with us at AASLD 2025, a leading conference for experts, professionals and scientists who are eager to explore the latest breakthroughts in hepatology research and learn more about our 3D in vitro liver disease solutions. 

The Liver Meeting, hosted by the American Association for the Study of Liver Disease, will take place from Friday, November 7th to Tuesday, November 11th in Washington D.C.

Meet our Team at Drug Discovery 2025

Francisco Verdeguer

Francisco Verdeguer, PhD

Vice President, Liver Disease

Arnab China, PhD

Business Development Manager

Scientific Poster at AASLD 2025

The lipid synthesis inhibitors ACC (Firsocosat) and DGAT2 (Ervogastat) reduce triglyceride content independently, but only Ervogastat also reduces fibrosis biomarkers in human liver spheroids

Date: Monday, November 10th, 2025 | 8:00 am - 5:00 pm  

Poster Number: 4079

Francisco Verdeguer

Francisco Verdeguer, PhD

Vice President, Liver Disease
Scroll to Top

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource